1 / 16

IDA Ireland / PharmaChemical Ireland Symposium

IDA Ireland / PharmaChemical Ireland Symposium The Road to Integrated Development and Manufacturing Jacintha Griffin Wyeth Newbridge September 23 rd 2009. Overview. The Road to Integrated Development & Manufacturing From technical transfer to Co-development

sian
Download Presentation

IDA Ireland / PharmaChemical Ireland Symposium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. IDA Ireland / PharmaChemical Ireland Symposium The Road to Integrated Development and Manufacturing Jacintha Griffin Wyeth Newbridge September 23rd 2009

  2. Overview The Road to Integrated Development & Manufacturing • From technical transfer to Co-development • Pharmaceutical Development Centre (PDC) business case • PDC Newbridge – Capability, facility and approach to integrated development & manufacturing • Development and Manufacturing Model - Future Opportunities and Challenges

  3. Wyeth NewbridgeThe Road to Integrated Development & Manufacturing Newbridge PDC Opens Newbridge PDC Construction Start New products organization & PDCs in Operation 2009 PDC Concept Approval 2008 Co-Development & Clinical Trial Supplies 2007 Technical Transfers & Process Optimisation 2005 2004 1992 - 2003

  4. Pharmaceutical Development Centre (PDC)Integrated Development and ManufacturingBusiness Case and Fiscal Supports Critical Supports in Justifying Business Case for Development centre: • Proven technical capability of supporting a large portfolio of solid dosage products • Demonstrated capability in collaborating with corporate R&D - Co-development • Collaboration with the IMB for rapid application, audit and receipt of IMP licence • Process optimization for marketed product portfolio - “Quality by re-Design” • Changing regulatory environment – impact of ICH Q8, 9, 10 • Government, IDA mandate and support • R&D Tax Credit System & capability grants • 12.5% Corporation Tax • IP Royalty Scheme

  5. PDC Charter and value proposition

  6. PDC NewbridgeMulti-Purpose Multi- ProductcGMPModule • Pilot Scale 5-50kg • 1/10th the commercial scale of pipeline products • SmallScale (<5kg Suite) • ‘Smart Development’ • Smaller Batches - Higher Velocity / Throughput • Supports API Cost and Supply Constraints Full Scalability to pilot and commercial scales • Process Characterisation Laboratory • Active and Excipient Functional Characterisation • Dedicated Analytical Development Laboratory • Flexible and Modular Design • Multiple Product Capability • Flexible Containment to handle potent compounds • “Future Proofed” for Next Generation Technologies • PAT/Data Management Infrastructure • Process Analytical Infrastructure for Real Time Acquisition, Aggregation, Analysis of Data

  7. Focus on Capability – Process Characterisation Molecular Particulate Bulk powder Final dosage form Spectroscopic: NIR Other chemical: Analysis to support physical characterisation (GQAD) Crystallographic: X-Ray Powder Diffraction (with Controlled Humidity Chamber) Microscopic: Scanning Electron Microscopy, Optical Microscopy, Image Analysis Thermal: Differential Scanning Calorimetry, Thermogravimetric Analysis Micromeritic: Specific Surface Area, Dynamic Vapour Sorption, Particle Size Analysis Mechanical: Texture Analysis Flow: Powder Rheometry Agglomeration: Air Jet Sieving Moisture: Loss on Drying, Water Activity Density: Bulk and Tapped Density, Helium Pycnometry, Envelope Density Coating Layer Thickness: Terahertz Pulsed Imaging Tablet Dimensions: Tablet Autotester

  8. PAT & Data Management Infrastructure Process Char. Lab LIMS SAP ERP BMS PAT Tools 1 – 5kg & 5 – 50kg Equipment

  9. Newbridge PDC Competencies • Cross Functional Team with Qualifications, Subject Matter Expertise and Practical Experience in: • Material Science • Powder Properties, Spectroscopic Techniques • Formulation Design • Pharmaceutics, Drug development, Pharmacokinetics • Process Design & Process Engineering • Process development • Analytical Method Design and Development • Spectroscopic Techniques, QbD for methods • Scale-up Expertise, Operational excellence and Lean manufacturing methodologies • Process Analytical Technology and Chemometrics expertise • IT, Automation and Data Management • Software Programming, Automation and Control Systems • Quality and Compliance • Regulatory understanding and application of CFR, GMP and ICH Q8, Q9 and Q10

  10. Organisationalstructure to deliver success • NewProducts and Process Development (NPPD) • Accountable for all new product activities from Proof of Concept (PoC) Key operating principles: • “Quality by Design” and “Quality Risk Management” principles embedded • API and Drug product accountabilities • Broad scope – clinical relevance and manufacturing optimization • Smart Development - Do more with less API using QbD and DoEs • Drive Finished Product dosage to support standardized technology platforms • PDC network part of NPPD

  11. New Products & Process Development (NPPD) and PDC Network New York PDC Phase 0, 1 Phase 2 Phase 3 Commercial Newbridge PDC Pipeline Newbridge, Ireland Corporate R&D 3rd Party Process Knowledge Pipeline Puerto Rico PDC Puerto Rico

  12. Building blocks for integrated Development & Manufacturing • Using Quality Risk Management techniques to drive the level of development activities required to yield the highest level of scientific knowledge • Understand inputs - physical characterisation techniques • Structured development programme - Understand Design space and interdependencies through DOEs • Data management infrastructure - design allows for the ability to Acquire, Analyse, Archive and Report Product and Process Data • Advanced chemometrics and statistical modelling to interrogate and understand data • Process Analytical Technology (PAT) for real time monitoring, prediction and control of quality attributes • Elimination of science of scale through knowledge management, model creation & Management • Regulatory filing (Design & Control space) and elimination of post approval changes

  13. PDC – Co-location with ManufacturingA Win - Win • Development co-located with manufacturing at commercial site - • Enhanced technical expertise to support both marketed and pipeline portfolios • Seamless knowledge transfer from late stage development through to commercial • Manufacturing requirements and input earlier into development programme • Influences standardized technology platform selection • Technical training and site upskilling • Reduction in regulatory complexity – Learn before filing • Deployment of PAT “with a purpose” – Pull not Push

  14. Looking to the future • Future Opportunities • Leverage from Competence Centres/Clusters – Solid state Pharmaceutical cluster (SSPC) etc • Build RD&I reputation – IP, publications, conferences • Business Process Innovation • RTR & Continuous Manufacturing • Industry Challenges • Availability of personnel with cross functional skills • Alignment and harmonisation of regulatory requirements of EMEA / Japan / FDA & other global markets

  15. Summary Build on manufacturing expertise and proven track record • Tech, transfers, scale up, operational excellence Build and deliver on business case • Drive an integrated & innovative approach to development and manufacturing • Focus on smart development and manufacturing excellence • Science driving compliance • Simple PAT solutions Grow a highly skilled, cross functional Team • Diverse backgrounds –formulation & process development, automation, statistics, chemometrics, analytics & engineering Overall result: • Enhanced process knowledge -Defined targets & ranges for CPP and CQA • Enhanced robustness, reduced COGs, elimination of scale up issues

  16. Thank You • Questions?

More Related